Biogen Inc. (BIIB, Financial), a leading biotechnology company, has received a reaffirmation of its stock rating by Needham, a reputable financial analyst firm. The analyst, Ami Fadia, reiterated the "Hold" rating on BIIB.
As of June 12, 2025, the rating for Biogen (BIIB, Financial) remains unchanged at "Hold," indicating that the stock is expected to perform in line with the market or industry over the coming period. This announcement by Needham does not include any target price adjustments, showing consistency in the firm’s outlook on the stock.
The decision to maintain a "Hold" rating suggests that investors could expect BIIB to experience stable performance, without significant volatility or downturns in its market valuation. No changes were made to the previous or current price targets, which aligns with analyst Ami Fadia's evaluation.
Investors and stakeholders should continue to watch for any new developments or strategic moves by Biogen (BIIB, Financial), as this could potentially impact future ratings and price forecasts.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 29 analysts, the average target price for Biogen Inc (BIIB, Financial) is $169.94 with a high estimate of $260.00 and a low estimate of $115.00. The average target implies an upside of 27.72% from the current price of $133.06. More detailed estimate data can be found on the Biogen Inc (BIIB) Forecast page.
Based on the consensus recommendation from 37 brokerage firms, Biogen Inc's (BIIB, Financial) average brokerage recommendation is currently 2.4, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Biogen Inc (BIIB, Financial) in one year is $211.27, suggesting a upside of 58.78% from the current price of $133.06. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Biogen Inc (BIIB) Summary page.
